Moderne Therapie der Sarkoidose

Lernziel

Die Sarkoidose ist eine generalisierte Erkrankung mit einer über 90 %igen Beteiligung der Lunge. Unverändert besteht die systemische Basistherapie der Erkrankung aus der Gabe eines hochdosierten Kortikosteroids. Die Heterogenität der Erkrankung und die vielen klinischen Phänotypen und der sehr unterschiedliche Organbefall erfordert ein individuell abgestimmtes Therapiekonzept. Ist die Erkrankung durch Steroide alleine nicht zu beeinflussen oder besteht eine Steroidintoleranz muss die Behandlung mit einem immunsuppressiven Medikament ergänzt werden. In dieser Übersicht werden die aktuelle Datenlage zur Sarkoidosetherapie erläutert und entsprechende Therapieempfehlungen gegeben.

• Literatur

• 1 Behr J, Costabel U. Interstitielle Lungenerkrankungen – historische Entwicklung, Status quo und Ausblick. Pneumologie 2010; 64: 573-576
• 2 Baughman RP, Nagai S, Balter M et al. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG task force. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 56-64
• 3 Pabst S, Skowasch D, Grohé C. Sarkoidose. Pneumologie 2012; 66: 96-110
• 4 Kirsten D, Costabel U. Pulmonale Sarcoidose. Pneumologie 2005; 59: 378-394
• 5 Prasse A, Müller-Quernheim J. Sarcoidose. Internist 2009; 50: 581-590
• 6 Grohé C, Pabst S, Baumgarten G et al. Toll-like receptor (TLR) 4 Asp229Gly and Thr399ILe polymorphisms are associated with a chronic progressive course of pulmonary sarcoidosis. Clin Exp Immunol 2006; 143: 420-426
• 7 Hofmann S, Fischer A, Till A et al. A genemone-wide association study reveals evidence of association with sarcoidosis at 6p12.1. Eur Respir J 2011; 38: 122-129
• 8 Zissel G, Prasse A, Müller-Quernheim J. Immunologic response of sarcoidosis. Semin Respir Crit Care Med 2010; 31: 390-403
• 9 Müller-Quernheim J, Schürmann M, Hofmann S et al. Genetik der Sarkoidose: Ein Schlüssel zum Verständnis ihrer Pathogenese. Pneumologie 2009; 63: 166-175
• 10 Chen ES, Moller DR. Sarcoidosis – scientific progress and clinical challenges. Nat Rev Rheumatol 2011; 7: 457-467
• 11 Constantino T, Digre K, Zimmerman P. Neuro-ophthalmic complications of sarcoidosis. Semin Neurol 2000; 20: 123-137
• 12 Sharma OP. Neurosarcoidosis: a personal perspective based on the study of 37 patients. Chest 1997; 112: 220-228
• 13 Costabel U. Sarcoidosis: clinical update. Eur Respir J 2001; 18: 56s-68s
• 14 British Thoracic Society and Standards of Care Committee. The diagnosis, assessment and treatment of diffuse parenchymal lung disease in adults. Thorax 1999; 54: 1-28
• 15 Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. ATS/ERS/WASOG statement on sarcoidosis. Eur Respir J 1999; 14: 735-737
• 16 Baughman RP, Costabel U, du Bois RM. Treatment of sarcoidosis. Clin Chest Med 2008; 29: 533-548
• 17 Gottlieb JE, Israel HL, Steiner RM et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997; 111: 623-631
• 18 Deutsche Gesellschaft für Pneumologie (DGP). Empfehlungen zur Diagnostik und Therapie der Sarkoidose. Pneumologie 1998; 52: 26-30
• 19 Wiegand JA, Brutsche M. Sarcoidosis is a multisystem disorder with variable prognosis – information for treating physicians. Swiss Med Wkly 2006; 136: 201-209
• 20 Wells AU, Hirani N. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zeeland and the Irish Thoracic Society. Thorax 2008; 63: 1-58
• 21 Barnard J, Newman LS. Sarcoidosis: immunology, rheumatic involvement, and therapeutics. Curr Opin Rheumatol 2001; 13: 84-91
• 22 Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev 2005; 2 CD001114
• 23 Alberts C, van der Mark TW, Jansen HM. Inhaled budesonide in pulmonary sarcoidosis: a double-blind, placebo-controlled study. Eur Respir J 1995; 8: 682-688
• 24 Coker RK. Guidelines for the use for corticosteroids in the treatment of pulmonary sarcoidosis. Drugs 2007; 67: 1139-1147
• 25 Bradley B, Branley HM, Egan JJ et al. Interstitital lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 2008; 63: 1-58
• 26 Lazar CA, Culver DA. Treatment of sarcoidosis. Semin Respir Crit Care Med 2010; 31: 501-518
• 27 Baughman RP, Nunes D. Therapy for sarcoidosis: evidence-based recommendations. Expert Rev Clin Immunol 2012; 8: 95-103
• 28 Sweiss NJ, Lower EE, Korsten P et al. Bone health issues in sarcoidosis. Curr Rheumatol Rep 2012; 13: 265-272
• 29 Vucinic V, Skodric-Trifunovic V, Ignjatovic S. How to diagnose and manage difficult problems of calcium metabolism in sarcoidosis: an evidencebased review. Curr Opin Pulm Med 2011; 17: 297-302
• 30 Pfeilschifter J (Hrsg). Die Leitlinien des Dachverbandes Osteologie zur Osteoporose. 1. Ausg. Bern: AZ Druck und Datentechnik GmbH; 2003
• 31 Lateef O, Shakoor N, Balk RA. Methotrexate pulmonary toxicity. Expert Opin Drug Saf 2005; 4: 723-730
• 32 Raghu G, DePaso WJ, Cain K et al. Azathioprine combined with prednisolone in the treatment of idipathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am Rev Respir Dis 1991; 144: 291-296
• 33 Baltzan M, Mehta S, Kirkham TH et al. Randomized trial of prolonged cholorquine therapy in advanced pulmonary sarcoidosis. Am J Respir Crit Care Med 1999; 160: 192-197
• 34 Paramothayan NS, Lasserson TJ, Walters EH. Immunosuppressive and cytotoxic therapy for pulmonary sarcoidosis. Cochrane Database Syst Rev 2006; 3 CD003536
• 35 Baughman RP, Drent M, Kavuru M et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802
• 36 Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology 2009; 14: 522-528
• 37 Judson MA, Baughman RP, Costabel U et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31: 1189-1196
• 38 Loza MJ, Brodmerkel C, du Bois RM et al. Inflammatory profile and response to anti-tumor necrosis factor therapy in patients with chronic pulmonary sarcoidosis. Clin Vaccine Immunology 2011; 18: 931-939
• 39 Hostettler KE, Studler U, Tamm M et al. Long-term treatment with infliximab in patients with sarcoidosis. Respiration 2012; 83: 218-224
• 40 Skoje IM, Wildhagen K, Omdal R. Development of sarcoidosis following etanercept treatment: a report of three cases. Rheumatol Int 2012; 32: 1049-1053
• 41 Zabel P, Entzian P, Dalhoff K et al. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155: 1665-1669
• 42 Park MK, Fontana Jr, Babaali H et al. Steroid-sparing effects of pentoxifylline in pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26: 121-131
• 43 Bachelez H, Senet P, Cadranel J et al. The use of tetracyclines for the treatment of sarcoidosis. Arch Dermatol 2001; 137: 69-73
• 44 Christie JD, Edwards LB, Aurora P et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report 2008. J Heart Lung Transplant 2008; 27: 957-969